| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Clinical Cancer Research, Vol 2, Issue 6 1049-1053, Copyright © 1996 by American Association for Cancer Research
ARTICLES |
DR Smith and HS Goh
Colorectal Cancer Research Laboratory, Department of Colorectal Surgery, Singapore General Hospital, Outram Road, Singapore 169608, Republic of Singapore.
The survival of 119 colorectal cancer patients was analyzed in the light of the overexpression status of the c-myc proto-oncogene mRNA and the point mutation status of the p53 tumor suppressor gene in the primary adenocarcinoma. The presence of >3 fold overexpression of c-myc mRNA in the primary tumor was found to be associated with a better prognosis than patients who evinced no overexpression (P = 0.02, log rank analysis). Point mutation of the p53 tumor suppressor gene was found to be associated with a poorer patient prognosis (P = 0.007, log rank analysis). Endogenous levels of c-myc and point mutation of p53 both contributed independently toward a poorer patient prognosis in Cox regression modeling. The better prognosis seen in patients who overexpress c-myc was offset when c-myc overexpression was coupled with a point mutated p53 gene. These results suggest that in colorectal adenocarcinoma c-myc deregulation leads to increased apoptotic death, but that this response may be modulated by a more downstream event such as point mutation of the p53 gene.
This article has been cited by other articles:
|
|
 |
|
  K. Nakao, K. R. Mehta, J. Fridlyand, D. H. Moore, A. N. Jain, A. Lafuente, J. W. Wiencke, J. P. Terdiman, and F. M. Waldman High-resolution analysis of DNA copy number alterations in colorectal cancer by array-based comparative genomic hybridization Carcinogenesis, August 1, 2004; 25(8): 1345 - 1357. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C Tselepis, C D Morris, D Wakelin, R Hardy, I Perry, Q T Luong, E Harper, R Harrison, S E A Attwood, and J A Z Jankowski Upregulation of the oncogene c-myc in Barrett's adenocarcinoma: induction of c-myc by acidified bile acid in vitro Gut, February 1, 2003; 52(2): 174 - 180. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. L. Cohn, W. B. London, D. Huang, H. M. Katzenstein, H. R. Salwen, T. Reinhart, J. Madafiglio, G. M. Marshall, M. D. Norris, and M. Haber MYCN Expression Is Not Prognostic of Adverse Outcome in Advanced-Stage Neuroblastoma With Nonamplified MYCN J. Clin. Oncol., November 1, 2000; 18(21): 3604 - 3613. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Bieche, I. Laurendeau, S. Tozlu, M. Olivi, D. Vidaud, R. Lidereau, and M. Vidaud Quantitation of MYC Gene Expression in Sporadic Breast Tumors with a Real-Time Reverse Transcription-PCR Assay Cancer Res., June 1, 1999; 59(12): 2759 - 2765. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
